| 1. |
- Shingles, L. J., et al.
(författare)
-
Monte Carlo radiative transfer for the nebular phase of Type Ia supernovae
- 2020
-
Ingår i: Monthly notices of the Royal Astronomical Society. - : OXFORD UNIV PRESS. - 0035-8711 .- 1365-2966. ; 492:2, s. 2029-2043
-
Tidskriftsartikel (refereegranskat)abstract
- We extend the range of validity of the ARTIS 3D radiative transfer code up to hundreds of days after explosion, when Type Ia supernovae (SNe Ia) are in their nebular phase. To achieve this, we add a non-local thermodynamic equilibrium population and ionization solver, a new multifrequency radiation field model, and a new atomic data set with forbidden transitions. We treat collisions with non-thermal leptons resulting from nuclear decays to account for their contribution to excitation, ionization, and heating. We validate our method with a variety of tests including comparing our synthetic nebular spectra for the well-known one-dimensional W7 model with the results of other studies. As an illustrative application of the code, we present synthetic nebular spectra for the detonation of a sub-Chandrasekhar white dwarf (WD) in which the possible effects of gravitational settling of Ne-22 prior to explosion have been explored. Specifically, we compare synthetic nebular spectra for a 1.06 M-circle dot WD model obtained when 5.5 Gyr of very efficient settling is assumed to a similar model without settling. We find that this degree of Ne-22 settling has only amodest effect on the resulting nebular spectra due to increased Ni-58 abundance. Due to the high ionization in sub-Chandrasekhar models, the nebular [Ni II] emission remains negligible, while the [Ni III] line strengths are increased and the overall ionization balance is slightly lowered in the model with Ne-22 settling. In common with previous studies of sub-Chandrasekhar models at nebular epochs, these models overproduce [Fe III] emission relative to [Fe II] in comparison to observations of normal SNe Ia.
|
|
| 2. |
- Hjorth, Thérése, 1985, et al.
(författare)
-
Sixteen-week multicentre randomised controlled trial to study the effect of the consumption of an oat beta-glucan-enriched bread versus a whole-grain wheat bread on glycaemic control among persons with pre-diabetes: a study protocol of the CarbHealth study
- 2022
-
Ingår i: BMJ Open. - : BMJ. - 2044-6055 .- 2044-6055. ; 12:8, s. e062066-
-
Tidskriftsartikel (refereegranskat)abstract
- INTRODUCTION: In 2012, the estimated global prevalence of pre-diabetes was 280 million, and the prevalence is expected to rise to 400 million by 2030. Oat-based foods are a good source of beta-glucans, which have been shown to lower postprandial blood glucose. Studies to evaluate the effectiveness of the long-term intake of beta-glucan-enriched bread as part of a habitual diet among individuals with pre-diabetes are needed. Therefore, we designed a multicentre intervention study in adults with pre-diabetes to investigate the effects of consumption of an oat-derived beta-glucan-enriched bread as part of a normal diet on glycated haemoglobin (HbA1c) in comparison to consumption of whole-grain wheat bread. METHODS AND ANALYSIS: The CarbHealth trial is a multicentre double-blind randomised controlled 16-week dietary intervention trial in participants 40-70 years of age with a body mass index of ≥27 kg/m2 and HbA1c of 35-50 mmol/mol. The study is conducted at four universities located in Norway, Sweden and Germany and uses intervention breads specifically designed for the trial by Nofima AS. The aim is to recruit 250 participants. The primary outcome is the difference in HbA1c between the intervention and the control groups. The main analysis will include intervention group, study centre and baseline HbA1c as independent variables in an analysis of covariance model. ETHICS AND DISSEMINATION: The study protocol was approved by respective ethical authorities in participating countries. The results of the study will be communicated through publication in international scientific journals and presentations at (inter)national conferences. TRIAL REGISTRATION NUMBER: NCT04994327.
|
|
